Table 2 Baseline Characteristics
N = 20 | |
|---|---|
Median age (years) (range) | 75.7 (27.9–87.1) |
Sex (n) | |
Male | 15 |
Female | 5 |
Immunotherapy received | |
Cemiplimab | 17 |
Pembrolizumab | 3 |
RECIST1.1 measurable disease at time of immunotherapy commencement | |
No | 3 |
Yes | 17 |
Stage of disease at time of immunotherapy commencement | |
Locally advanced disease without regional nodal involvement | 16 |
Locally advanced disease including regional nodal involvement | 4 |
Distant metastatic | 0 |